|
|
|
|
|
|
|
|
|
07.08.25 - 12:00
|
1 Reason to Buy MindMed (MNMD) (Fool)
|
|
|
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company....
|
|
|
|
|
|
|
24.07.25 - 13:03
|
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the devel...
|
|
|
|
|
21.07.25 - 17:24
|
MindMed Shares Surge 10% As Psychedelics Gain Political Momentum Within Trump Admin (ZeroHedge)
|
|
|
MindMed Shares Surge 10% As Psychedelics Gain Political Momentum Within Trump Admin
Shares of MindMed and other psychedelic names are bid this morning as psychedelic therapies are experiencing a major inflection point in U.S. policy and public awareness, with bipartisan political support, a surge of veteran advocacy, and rising investor interest—all despite significant regulatory headwinds.
MindMed, one of our favorite psychedelic names, has been in a decisive uptrend since news first broke on July 16 that the Trump administration could be interested in fast-tracking the class of drugs.
Short interest in MindMed has risen throughout 2024 and recently hit a 3 year high of nearly 12M shares.
Health Secretary Robert F. Kennedy Jr. recently signaled a dramatic shift in federal posture, telling lawmakers he expects psychedelic therapies for PTSD and depression to be available within 12 months.
“This line of therapeutics has tremendous advantage if given in a clinical setting and we are working ...
|
|
|
14.07.25 - 22:06
|
MindMed Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 96,400 common shares of the Company (the "Options"), with effective grant dates of July 7, 2025 and July 14, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's ...
|
|
|
|
|
|
|
|
|
|
|
09.06.25 - 22:03
|
MindMed Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the last trading day on which MindMed's common shares traded prior to the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment...
|
|
|
|
|
|
|
27.05.25 - 13:06
|
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--$MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
“Brandi joins MindMed at a pivotal moment for the company, bringing with her a powerful combination of financial acumen, strategic vision, and deep biotech sector expertise,” said Rob Barrow, Chief Executive Officer of Min...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
